- Home
- YGMZ vs ENTX Comparison
YGMZ vs ENTX Comparison
Compare YGMZ & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- ENTX
- Stock Information
- Founded
- YGMZ 2002
- ENTX 2010
- Country
- YGMZ China
- ENTX Israel
- Employees
- YGMZ N/A
- ENTX N/A
- Industry
- YGMZ Transportation Services
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YGMZ Consumer Discretionary
- ENTX Health Care
- Exchange
- YGMZ Nasdaq
- ENTX Nasdaq
- Market Cap
- YGMZ N/A
- ENTX 69.6M
- IPO Year
- YGMZ 2020
- ENTX 2018
- Fundamental
- Price
- YGMZ $0.72
- ENTX $1.70
- Analyst Decision
- YGMZ
- ENTX Strong Buy
- Analyst Count
- YGMZ 0
- ENTX 1
- Target Price
- YGMZ N/A
- ENTX $10.00
- AVG Volume (30 Days)
- YGMZ 40.4K
- ENTX 52.4K
- Earning Date
- YGMZ 01-01-0001
- ENTX 03-28-2025
- Dividend Yield
- YGMZ N/A
- ENTX N/A
- EPS Growth
- YGMZ N/A
- ENTX N/A
- EPS
- YGMZ N/A
- ENTX N/A
- Revenue
- YGMZ $55,805,416.00
- ENTX $181,000.00
- Revenue This Year
- YGMZ N/A
- ENTX N/A
- Revenue Next Year
- YGMZ N/A
- ENTX N/A
- P/E Ratio
- YGMZ N/A
- ENTX N/A
- Revenue Growth
- YGMZ N/A
- ENTX N/A
- 52 Week Low
- YGMZ $0.64
- ENTX $1.41
- 52 Week High
- YGMZ $4.35
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- YGMZ 36.71
- ENTX 33.66
- Support Level
- YGMZ $0.80
- ENTX $1.85
- Resistance Level
- YGMZ $0.99
- ENTX $2.02
- Average True Range (ATR)
- YGMZ 0.11
- ENTX 0.10
- MACD
- YGMZ -0.02
- ENTX -0.01
- Stochastic Oscillator
- YGMZ 0.24
- ENTX 11.57
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.